- Design, synthesis, and in vitro bioactivity evaluation of fluorine-containing analogues for sphingosine-1-phosphate 2 receptor
-
Twenty eight new aryloxybenzene analogues were synthesized and their in vitro binding potencies toward S1PR2 were determined using a [32P]S1P competitive binding assay. Out of these new analogues, three compounds, 28c (IC50 = 29.9 ± 3.9 nM), 28e (IC50 = 14.6 ± 1.5 nM), and 28g (IC50 = 38.5 ± 6.3 nM) exhibited high binding potency toward S1PR2 and high selectivity over the other four receptor subtypes (S1PR1, 3, 4, and 5; IC50 > 1000 nM). Each of the three potent compounds 28c, 28e, and 28g contains a fluorine atom that will allow to develop F-18 labeled PET radiotracers for imaging S1PR2.
- Luo, Zonghua,Liu, Hui,Klein, Robyn S.,Tu, Zhude
-
p. 3619 - 3631
(2019/07/05)
-
- Design and optimization of quinazoline derivatives as melanin concentrating hormone receptor 1 (MCHR1) antagonists: Part 2
-
Melanin concentrating hormone receptor 1 (MCHR1) antagonists have potential for the treatment of obesity and several CNS disorders. In the preceding article, we have described a novel series of quinazolines as MCHR1 antagonists and demonstrated in vivo proof of principle with an early lead. Herein we describe the detailed SAR and SPR studies to identify an optimized lead candidate having good efficacy in a sub-chronic DIO model with a good cardiovascular safety window.
- Sasmal, Sanjita,Balasubrahmanyam,Kanna Reddy, Hariprasada R.,Balaji, Gade,Srinivas, Gujjary,Cheera, Srisailam,Abbineni, Chandrasekhar,Sasmal, Pradip K.,Khanna, Ish,Sebastian,Jadhav, Vikram P.,Singh, Manvendra P.,Talwar, Rashmi,Suresh,Shashikumar, Dhanya,Harinder Reddy,Sihorkar,Frimurer, Thomas M.,Rist, ?ystein,Elster, Lisbeth,H?gberg, Thomas
-
supporting information; experimental part
p. 3163 - 3167
(2012/06/04)
-
- Benzimidazolidinone derivatives as muscarinic agents
-
Benzimidazolidinone derivative compounds, which increase acetylcholine signaling or effect in the brain, and highly selective muscarinic agonists, particularly for the M1 and/or M4 receptor subtypes, pharmaceutical compositions comprising the same, as well as methods of treating psychosis using these compounds are disclosed.
- -
-
Page/Page column 38
(2010/02/06)
-